July 21, 2014 – Lung Cancer Trial
Podcast: Download (Duration: 1:06 — 1.0MB)
Anchor lead: A new national effort takes aim at one type of lung cancer, Elizabeth Tracey reports
Can treatment for one type of lung cancer be rapidly advanced with the participation of pharmaceutical companies, hospitals, geneticists and researchers? That’s the hope of a newly launched initiative called the Lung Map Study. William Nelson, director of the Kimmel Cancer Center at Johns Hopkins, applauds the effort.
Nelson: Literally five different major companies have been brought together willing to participate in this kind of trial, and large clinical research network has been assembled, called the National Clinical Trials Network or NCTN, which encompasses over 200 centers, so the access for being able to participate in this trial for anyone who has lung cancer will be really extraordinary and in many ways unprecedented. And so the trial targets an advanced squamous cell cancer of the lung that’s about one-quarter of all lung cancers. :31
At Johns Hopkins, I’m Elizabeth Tracey.